Compugen Ltd. (Nasdaq:CGEN) and the Pulmonary Fibrosis Foundation announced that the Pulmonary Fibrosis Foundation will provide a grant to scientists at the University of Pittsburgh Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease to independently evaluate the therapeutic potential of CGEN-25009 for the treatment of idiopathic pulmonary fibrosis (IPF), a devastating disease with no current effective treatment and which is estimated to affect more than five million people worldwide.



Read the full article and the disclaimer at:http://bestotc.com/18812/stock-alerts/cgen-svnt-mjgcf-cpix-stocks-to-watch-by-bestotccom/